Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
DRUG:
BL-M11D1
Sponsor
SystImmune Inc.